Skip to content

Only three countries conduct almost 50% of all COVID-19 medical studies

Only three countries conduct almost 50% of all COVID-19 medical studies

Only three countries have emerged as frontrunners in conducting coronavirus research by accounting for almost half of the global Covid-19 medical studies. Data retrieved from Finbold.com Coronavirus Research Index indicates that three countries have conducted 46.93% of the 2,450 total studies as of August 30th. 

From the data, the United States ranks top with 620 studies representing 25.30% followed by France at 386 or 15.75%. The United Kingdom comes a distant third with 144 studies or 5.87%. In general, the top five countries with most studies are among the most impacted with the pandemic. 

Notably, China where the virus originated ranks in the seventh spot with 96 studies. On the other hand, Brazil is the only South American country in the top ten list with 76 coronavirus related studies. 

As more countries were hit by the virus, the number of Covid-19 medical studies gradually increased. By the end of May, a total of 1,141 studies were being conducted. Come August, the number grew by a whopping 114.72% to 2,450.

Importance of accelerating Covid-19 studies 

When the pandemic spread across the world, it immediately propelled medical research to the forefront of public attention. Initially, experts in infectious diseases, epidemiology, public health, modeling, and economics became the focus of many as they played a key role in improving Covid-19 management. 

The studies were meant to accelerate diagnosis, vaccines, and therapeutics for the virus. It called for more investment in terms of resources since scientists did not have a blueprint to learn from. In recent history, no pandemic of such magnitude has been experienced. 

Successful studies and a possible cure or vaccine will act as a major boost to the global economy. The health crisis crippled the global economy with the stock market plunging to all times lows. Already, the markets have shown signs of recovery with news of possible success from ongoing clinical trials for vaccines. 

It is no surprise that the United States is leading the way in regards to coronavirus studies considering its the most hit country globally. The country now has recorded at least six million cases with about 183,000 deaths. 

For vaccines, there are several stages involved. After the initial laboratory and animal tests, they enter the first phase of human trials and primarily analyze safety and immune responses. They enter the second phase which is the larger versions of the first phase trials. 

Under the third phase, scientists attempt to determine whether a vaccine works by comparing people who receive it with those who are given a placebo shot and, over several months or years, seeing how many in each group get infected. 

Russia, China announce vaccine success outside clinical trials 

China and Russia have already approved the limited use of COVID-19 vaccines outside of clinical trials. The move which has raised safety concerns baffled many while at the same time leading to criticism.

As scientists continued to study the virus, there were calls for protecting and strengthening research. For most countries, there were thoughtful and concerted efforts on the part of governments, funders, and research institutions to put in place sustainable research systems. Additionally, the pandemic has evolved the need for governments to be prepared for such occurrences in the future. 

The Finbold.com Coronavirus Research Index analyzes all the active clinical COVID-19 studies reported to ClinicalTrials.gov. The index shows countries that are putting in the biggest efforts in understanding the coronavirus thus helping to find an effective way to treat the disease.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account?

Services

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.